{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:26:18Z","timestamp":1793049978269,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","funder":[{"name":"LEO Pharma"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s13555-016-0137-2","type":"journal-article","created":{"date-parts":[[2016,8,8]],"date-time":"2016-08-08T11:47:15Z","timestamp":1470656835000},"page":"599-626","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Ingenol Disoxate: A Novel 4-Isoxazolecarboxylate Ester of Ingenol with Improved Properties for Treatment of Actinic Keratosis and Other Non-Melanoma Skin Cancers"],"prefix":"10.1007","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3331-866X","authenticated-orcid":false,"given":"Malene","family":"Bertelsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Stahlhut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Grue-S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xifu","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gitte Bach","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kresten","family":"Skak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen Margrethe","family":"Engell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"H\u00f6gberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,8]]},"reference":[{"issue":"Suppl 2","key":"137_CR1","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1365-2133.2007.08267.x","volume":"157","author":"J Roewert-Huber","year":"2007","unstructured":"Roewert-Huber J, Stockfleth E, Kerl H. Pathology and pathobiology of actinic (solar) keratosis\u2014an update. Br J Dermatol. 2007;157(Suppl 2):18\u201320.","journal-title":"Br J Dermatol"},{"issue":"3","key":"137_CR2","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1590\/S0365-05962012000300012","volume":"87","author":"JV Schmitt","year":"2012","unstructured":"Schmitt JV, Miot HA. Actinic keratosis: a clinical and epidemiological revision. An Bras Dermatol. 2012;87(3):425\u201334.","journal-title":"An Bras Dermatol"},{"issue":"1 Suppl 1","key":"137_CR3","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.jaad.2012.09.053","volume":"68","author":"B Berman","year":"2013","unstructured":"Berman B, Cockerell CJ. Pathobiology of actinic keratosis: ultraviolet-dependent keratinocyte proliferation. J Am Acad Dermatol. 2013;68(1 Suppl 1):S10\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"137_CR4","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1684\/ejd.2013.1923","volume":"23","author":"D Nashan","year":"2013","unstructured":"Nashan D, Meiss F, Muller M. Therapeutic strategies for actinic keratoses\u2013a systematic review. Eur J Dermatol. 2013;23(1):14\u201332.","journal-title":"Eur J Dermatol"},{"issue":"4","key":"137_CR5","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s40257-013-0023-y","volume":"14","author":"A Samrao","year":"2013","unstructured":"Samrao A, Cockerell CJ. Pharmacotherapeutic management of actinic keratosis: focus on newer topical agents. Am J Clin Dermatol. 2013;14(4):273\u20137.","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"137_CR6","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s40257-013-0023-y","volume":"14","author":"A Samrao","year":"2013","unstructured":"Samrao A, Cockerell CJ. Pharmacotherapeutic management of actinic keratosis: focus on newer topical agents. Am J Clin Dermatol. 2013;14(4):273\u20137.","journal-title":"Am J Clin Dermatol"},{"issue":"11","key":"137_CR7","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1056\/NEJMoa1111170","volume":"366","author":"M Lebwohl","year":"2012","unstructured":"Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B. Ingenol mebutate gel for actinic keratosis. N Engl J Med. 2012;366(11):1010\u20139.","journal-title":"N Engl J Med"},{"issue":"1","key":"137_CR8","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s13555-012-0008-4","volume":"2","author":"FR Ali","year":"2012","unstructured":"Ali FR, Wlodek C, Lear JT. The role of ingenol mebutate in the treatment of actinic keratoses. Dermatol Ther (Heidelb). 2012;2(1):8.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"27","key":"137_CR9","doi-asserted-by":"crossref","first-page":"5115","DOI":"10.1002\/ejoc.201200733","volume":"2012","author":"A Vasas","year":"2015","unstructured":"Vasas A, Redei D, Csupor D, Molnar J, Hohmann J. Diterpenes from European Euphorbia species serving as prototypes for natural-product-based drug discovery. Eur J Org Chem. 2015;2012(27):5115\u201330.","journal-title":"Eur J Org Chem"},{"issue":"3","key":"137_CR10","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1055\/s-2000-8568","volume":"66","author":"J Hohmann","year":"2000","unstructured":"Hohmann J, Evanics F, Berta L, Bartok T. Diterpenoids from Euphorbia peplus. Planta Med. 2000;66(3):291\u20134.","journal-title":"Planta Med"},{"key":"137_CR11","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1055\/s-0032-1317415","volume":"23","author":"X Liang","year":"2012","unstructured":"Liang X, Grue-Sorensen G, Petersen A, Hoegberg T. Semisynthesis of ingenol 3-angelate (PEP005): efficient stereoconservative angeloylation of alcohols. Synlett. 2012;23:2647\u201352.","journal-title":"Synlett"},{"issue":"6","key":"137_CR12","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamadermatol.2013.2766","volume":"149","author":"M Lebwohl","year":"2013","unstructured":"Lebwohl M, Shumack S, Stein GL, Melgaard A, Larsson T, Tyring SK. Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. JAMA Dermatol. 2013;149(6):666\u201370.","journal-title":"JAMA Dermatol"},{"issue":"10","key":"137_CR13","first-page":"1181","volume":"11","author":"M Stahlhut","year":"2012","unstructured":"Stahlhut M, Bertelsen M, Hoyer-Hansen M, Svendsen N, Eriksson AH, Lord JM, et al. Ingenol mebutate: induced cell death patterns in normal and cancer epithelial cells. J Drugs Dermatol. 2012;11(10):1181\u201392.","journal-title":"J Drugs Dermatol"},{"issue":"8","key":"137_CR14","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s00262-008-0458-9","volume":"57","author":"P Hampson","year":"2008","unstructured":"Hampson P, Kavanagh D, Smith E, Wang K, Lord JM, Ed RG. The antitumor agent, ingenol-3-angelate (PEP005), promotes the recruitment of cytotoxic neutrophils by activation of vascular endothelial cells in a PKC-delta dependent manner. Cancer Immunol Immunother. 2008;57(8):1241\u201351.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"137_CR15","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3390\/toxins2010174","volume":"2","author":"E Ersvaer","year":"2010","unstructured":"Ersvaer E, Kittang AO, Hampson P, Sand K, Gjertsen BT, Lord JM, et al. The protein kinase C agonist PEP005 (ingenol 3-angelate) in the treatment of human cancer: a balance between efficacy and toxicity. Toxins (Basel). 2010;2(1):174\u201394.","journal-title":"Toxins (Basel)"},{"issue":"3","key":"137_CR16","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jaad.2010.12.038","volume":"66","author":"RH Rosen","year":"2012","unstructured":"Rosen RH, Gupta AK, Tyring SK. Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: rapid lesion necrosis followed by lesion-specific immune response. J Am Acad Dermatol. 2012;66(3):486\u201393.","journal-title":"J Am Acad Dermatol"},{"issue":"20","key":"137_CR17","doi-asserted-by":"crossref","first-page":"5624","DOI":"10.1016\/j.bmcl.2013.08.038","volume":"23","author":"X Liang","year":"2013","unstructured":"Liang X, Grue-Sorensen G, Mansson K, Vedso P, Soor A, Stahlhut M, et al. Syntheses, biological evaluation and SAR of ingenol mebutate analogues for treatment of actinic keratosis and non-melanoma skin cancer. Bioorg Med Chem Lett. 2013;23(20):5624\u20139.","journal-title":"Bioorg Med Chem Lett"},{"issue":"1","key":"137_CR18","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bmcl.2013.11.073","volume":"24","author":"G Grue-Sorensen","year":"2014","unstructured":"Grue-Sorensen G, Liang X, Mansson K, Vedso P, Dahl SM, Soor A, et al. Synthesis, biological evaluation and SAR of 3-benzoates of ingenol for treatment of actinic keratosis and non-melanoma skin cancer. Bioorg Med Chem Lett. 2014;24(1):54\u201360.","journal-title":"Bioorg Med Chem Lett"},{"issue":"47","key":"137_CR19","doi-asserted-by":"crossref","first-page":"14044","DOI":"10.1002\/anie.201507977","volume":"54","author":"Y Jin","year":"2015","unstructured":"Jin Y, Yeh CH, Kuttruff CA, Jorgensen L, Dunstl G, Felding J, et al. CH oxidation of ingenanes enables potent and selective protein kinase C isoform activation. Angew Chem Int Ed Engl. 2015;54(47):14044\u20138.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"8","key":"137_CR20","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1158\/0008-5472.CAN-03-2837","volume":"64","author":"SM Ogbourne","year":"2004","unstructured":"Ogbourne SM, Suhrbier A, Jones B, Cozzi SJ, Boyle GM, Morris M, et al. Antitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and necrotic cell death. Cancer Res. 2004;64(8):2833\u20139.","journal-title":"Cancer Res"},{"issue":"48","key":"137_CR21","doi-asserted-by":"crossref","first-page":"28495","DOI":"10.1074\/jbc.270.48.28495","volume":"270","author":"AC Newton","year":"1995","unstructured":"Newton AC. Protein kinase C: structure, function, and regulation. J Biol Chem. 1995;270(48):28495\u20138.","journal-title":"J Biol Chem"},{"issue":"7","key":"137_CR22","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1096\/fasebj.9.7.7737456","volume":"9","author":"Y Nishizuka","year":"1995","unstructured":"Nishizuka Y. Protein kinase C and lipid signaling for sustained cellular responses. FASEB J. 1995;9(7):484\u201396.","journal-title":"FASEB J"},{"issue":"9","key":"137_CR23","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1158\/0008-5472.CAN-03-3403","volume":"64","author":"N Kedei","year":"2004","unstructured":"Kedei N, Lundberg DJ, Toth A, Welburn P, Garfield SH, Blumberg PM. Characterization of the interaction of ingenol 3-angelate with protein kinase C. Cancer Res. 2004;64(9):3243\u201355.","journal-title":"Cancer Res"},{"issue":"4","key":"137_CR24","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/1523-1747.ep12365967","volume":"101","author":"GJ Fisher","year":"1993","unstructured":"Fisher GJ, Tavakkol A, Leach K, Burns D, Basta P, Loomis C, et al. Differential expression of protein kinase C isoenzymes in normal and psoriatic adult human skin: reduced expression of protein kinase C-beta II in psoriasis. J Invest Dermatol. 1993;101(4):553\u20139.","journal-title":"J Invest Dermatol"},{"key":"137_CR25","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1158\/1535-7163.MCT-15-0023-T","volume":"14","author":"SN Freiberger","year":"2015","unstructured":"Freiberger SN, Cheng PF, Iotzova-Weiss G, Neu J, Liu Q, Dziunycz PJ, et al. Ingenol mebutate signals via PKC\/MEK\/ERK in keratinocytes and induces interleukin decoy receptors IL1R2 and IL13RA2. Mol Cancer Ther. 2015;14:2132\u201342.","journal-title":"Mol Cancer Ther"},{"issue":"10","key":"137_CR26","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1038\/jid.2009.74","volume":"129","author":"A Jerome-Morais","year":"2009","unstructured":"Jerome-Morais A, Rahn HR, Tibudan SS, Denning MF. Role for protein kinase C-alpha in keratinocyte growth arrest. J Invest Dermatol. 2009;129(10):2365\u201375.","journal-title":"J Invest Dermatol"},{"issue":"4","key":"137_CR27","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1182\/blood-2004-10-4117","volume":"106","author":"P Hampson","year":"2005","unstructured":"Hampson P, Chahal H, Khanim F, Hayden R, Mulder A, Assi LK, et al. PEP005, a selective small-molecule activator of protein kinase C, has potent antileukemic activity mediated via the delta isoform of PKC. Blood. 2005;106(4):1362\u20138.","journal-title":"Blood"},{"issue":"12","key":"137_CR28","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1158\/1535-7163.1651.3.12","volume":"3","author":"SK Gillespie","year":"2004","unstructured":"Gillespie SK, Zhang XD, Hersey P. Ingenol 3-angelate induces dual modes of cell death and differentially regulates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in melanoma cells. Mol Cancer Ther. 2004;3(12):1651\u20138.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"137_CR29","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1083\/jcb.120.1.217","volume":"120","author":"AA Dlugosz","year":"1993","unstructured":"Dlugosz AA, Yuspa SH. Coordinate changes in gene expression which mark the spinous to granular cell transition in epidermis are regulated by protein kinase C. J Cell Biol. 1993;120(1):217\u201325.","journal-title":"J Cell Biol"},{"issue":"11","key":"137_CR30","doi-asserted-by":"crossref","first-page":"8123","DOI":"10.4049\/jimmunol.177.11.8123","volume":"177","author":"JM Challacombe","year":"2006","unstructured":"Challacombe JM, Suhrbier A, Parsons PG, Jones B, Hampson P, Kavanagh D, et al. Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelate. J Immunol. 2006;177(11):8123\u201332.","journal-title":"J Immunol"},{"issue":"4","key":"137_CR31","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1038\/jid.2011.418","volume":"132","author":"SJ Cozzi","year":"2012","unstructured":"Cozzi SJ, Ogbourne SM, James C, Rebel HG, de Gruijl FR, Ferguson B, et al. Ingenol mebutate field-directed treatment of UVB-damaged skin reduces lesion formation and removes mutant p53 patches. J Invest Dermatol. 2012;132(4):1263\u201371.","journal-title":"J Invest Dermatol"},{"key":"137_CR32","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1038\/cddis.2011.40","volume":"2","author":"T Hara","year":"2011","unstructured":"Hara T, Miyazaki M, Hakuno F, Takahashi S, Chida K. PKCeta promotes a proliferation to differentiation switch in keratinocytes via upregulation of p27Kip1 mRNA through suppression of JNK\/c-Jun signaling under stress conditions. Cell Death Dis. 2011;2:e157.","journal-title":"Cell Death Dis"},{"issue":"9","key":"137_CR33","doi-asserted-by":"crossref","first-page":"5199","DOI":"10.1128\/MCB.18.9.5199","volume":"18","author":"M Ohba","year":"1998","unstructured":"Ohba M, Ishino K, Kashiwagi M, Kawabe S, Chida K, Huh NH, et al. Induction of differentiation in normal human keratinocytes by adenovirus-mediated introduction of the eta and delta isoforms of protein kinase C. Mol Cell Biol. 1998;18(9):5199\u2013207.","journal-title":"Mol Cell Biol"},{"issue":"8","key":"137_CR34","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1038\/jid.2010.108","volume":"130","author":"G Adhikary","year":"2010","unstructured":"Adhikary G, Chew YC, Reece EA, Eckert RL. PKC-delta and -eta, MEKK-1, MEK-6, MEK-3, and p38-delta are essential mediators of the response of normal human epidermal keratinocytes to differentiating agents. J Invest Dermatol. 2010;130(8):2017\u201330.","journal-title":"J Invest Dermatol"},{"issue":"5","key":"137_CR35","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1023\/A:1015810312465","volume":"9","author":"RO Potts","year":"1992","unstructured":"Potts RO, Guy RH. Predicting skin permeability. Pharm Res. 1992;9(5):663\u20139.","journal-title":"Pharm Res"},{"key":"137_CR36","doi-asserted-by":"crossref","unstructured":"Cronin MTD, Hewitt M. Comprehensive medicinal chemistry II, 2nd edn. Elsevier, Amsterdam; 2007. pp 725\u201344.","DOI":"10.1016\/B0-08-045044-X\/00285-6"},{"issue":"2","key":"137_CR37","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/toxsci\/59.2.198","volume":"59","author":"I Kimber","year":"2001","unstructured":"Kimber I, Basketter DA, Berthold K, Butler M, Garrigue JL, Lea L, et al. Skin sensitization testing in potency and risk assessment. Toxicol Sci. 2001;59(2):198\u2013208.","journal-title":"Toxicol Sci"},{"issue":"2","key":"137_CR38","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/bjd.14245","volume":"174","author":"S Sinnya","year":"2016","unstructured":"Sinnya S, Tan JM, Prow TW, Primiero C, McEniery E, Selmer J, et al. A randomized, phase IIa exploratory trial to assess the safety and preliminary efficacy of LEO 43204 in patients with actinic keratosis. Br J Dermatol. 2016;174(2):305\u201311.","journal-title":"Br J Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-016-0137-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T11:12:42Z","timestamp":1657019562000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13555-016-0137-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,8]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["137"],"URL":"https:\/\/doi.org\/10.1007\/s13555-016-0137-2","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,8]]}}}